Ibrutinib

Ibrutinib is a first-in-class, orally administered small-molecule inhibitor of Bruton's tyrosine kinase (BTK), the signaling enzyme that relays B-cell receptor (BCR) engagement to downstream survival pathways. It forms an irreversible covalent bond with cysteine-481 in the ATP-binding site — with hydrogen bonding at Glu475 and Met477 — permanently silencing the kinase in each molecule it meets, so activity outlasts the drug's short plasma half-life and permits once-daily dosing. Blocking BTK cuts the survival and proliferation signals malignant B cells depend on, including flux through the PI3K/Akt signaling pathway, and also disrupts the adhesion and chemokine responses that keep those cells in protective tissue niches; the transient lymphocytosis seen on starting treatment is malignant cells being displaced into the blood rather than disease progression. Approved in 2013, it established BTK inhibition as a pillar of hematologic oncology.

Its indications span B-cell neoplasms including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM) and marginal zone lymphoma (MZL). The covalent chemistry that makes it potent is also the source of its characteristic toxicity: cysteine-481 is not unique to BTK, and off-target inhibition of related kinases including EGFR, ITK and TEC family members contributes to rash, diarrhea and bleeding, while the mechanism of atrial fibrillation remains incompletely understood; these toxicities limit long-term use. Next-generation covalent inhibitors such as acalabrutinib and zanubrutinib were designed for greater selectivity and carry less of that burden, which is the principal reason they have displaced ibrutinib in several settings.

Resistance most often arises by mutation of cysteine-481 itself, removing the anchor the covalent bond requires, or by activating mutations in PLCG2 downstream of the kinase — a failure mode that prompted non-covalent BTK inhibitors binding elsewhere, and BTK-directed degraders that remove the protein rather than inhibit it. Combination strategies, mechanisms of resistance and novel BTK-targeting compounds remain active areas of investigation.